Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data
Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data
Body unavailable. Use the original source.
Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.